The Latest Cardiac and Vascular News
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohort of 153 patients in the CONVERGE IDE clinical trial. The CONVERGE IDE trial is a landmark prospective, randomized trial […]
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) — The Sarcomeric Human Cardiomyopathy Registry (SHaRe) and MyoKardia, Inc. (Nasdaq: MYOK) announced today the publication of results from a multicenter, international, longitudinal study of data from nearly 4,600 patients with hypertrophic cardiomyopathy (HCM), the largest comprehensive HCM cohort assembled to […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York on Friday, September 14, 2018. Management is scheduled to present […]
MUNICH, August 20, 2018 /PRNewswire/ — Satellite symposium will highlight the breadth of evidence collected since the establishment of the registry in2009 An analysis of the comparative effectiveness of oral anticoagulants in everyday practice will be presented The economic burden of atrial fibrillation (AF) in nine European countries will be evaluated The […]
SAN FRANCISCO, July 10, 2018 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that results of the mHealth Screening to Prevent Strokes (mSToPS) study, which showed increased detection of asymptomatic atrial fibrillation (AF) in high-risk […]
CHICAGO, June 29, 2018 /PRNewswire-USNewswire/ — The American Heart Association recently selected Northwestern Medicine as one of six centers to be part of a new, grant-funded national network dedicated to researching and understanding the causes of atrial fibrillation, the most common type of irregular heartbeat. At Northwestern, a $3.7 million grant will fund research specifically on […]
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes Baheal as the exclusive distributor for AtriCure, and replaces the […]
BROOMFIELD, Colo.–(BUSINESS WIRE)–ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc. (NYSE:MDT), a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA’s proposed […]
MARLBOROUGH, Mass., Sept. 27, 2017 /PRNewswire/ — CardioFocus, Inc. today announced the European CE Mark approval of the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of atrial fibrillation (AF). The Excalibur Balloon leverages the proven universal balloon design of the company’s FDA-approved HeartLight® Endoscopic Ablation System and introduces an advanced feature set that optimizes the speed […]
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the AtriClip PRO•V™ Left Atrial Appendage (LAA) Exclusion System in the United States. The new device offers an open-ended design combined with a tip-first closure […]
